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Chronic pancreatitis (CP) is defined by irreversible damage to the pancreas as a result of
inflammation-driven pancreatic tissue destruction and fibrosis occurring over many years.
The disorder is complex, with multiple etiologies leading to the same tissue pathology,
and unpredictable clinical courses with variable pain, exocrine and endocrine organ
dysfunction, and cancer. Underlying genetic variants are central CP susceptibility and
progression. Three genes, with Mendelian genetic biology (PRSS1, CFTR, and SPINK1)
have been recognized for over a decade, and little progress has been made since then.
Furthermore, application of high-throughput genetic techniques, including genome-wide
association studies (GWAS) and next generation sequencing (NGS) will provide a large
volume of new genetic variants that are associated with CP, but with small independent
effect that are impossible to apply in the clinic. The problem of interpretation is using the
old framework of the germ theory of disease to understand complex genetic disorders.
To understand these variants and translate them into clinically useful information requires
a new framework based on modeling and simulation of physiological processes with or
without genetic, metabolic and environmental variables considered at the cellular and
organ levels, with integration of the immune system, nervous system, tissue injury and
repair system, and DNA repair system. The North American Pancreatitis Study 2 (NAPS2)
study was designed to capture this type of date and construct a time line to understand
and later predict rates of disease progression from the initial symptom to end-stage
disease. This effort is needed to target the etiology of pancreatic dysfunction beginning at
the first signs of disease and thereby prevent the development of irreversible damage and
the complications of CP. The need for a new framework and the rational for implementing
it into clinical practice are described.
Keywords: pancreatitis, cystic fibrosis, genetics, next generation sequencing, GWAS, systems biology,
inflammation
INTRODUCTION
Classic Mendelian genetics plays a small but significant role in
chronic pancreatitis (CP). Three syndromes are well described
including autosomal dominant hereditary pancreatitis (HP),
autosomal recessive cystic fibrosis (CF), and autosomal recessive
familial pancreatitis from homozygous or compound heterozy-
gous SPINK1 mutations. The biology and pathology of these
genes, plus lower risk genes chymotrypsin C (CTRC) and calcium
sensing receptor (CASR), have recently been reviewed (Teich and
Mossner, 2008; Chen and Ferec, 2009; Whitcomb, 2010; Larusch
and Whitcomb, 2011; Chen and Ferec, 2012). However, these
syndromes make up less than 10% of CP cases in most clinical
populations.
It is now recognized that non-Mendelian, complex genetic
conditions are far more common and therefore of greater rele-
vance. Complex genetics include gene-environment or gene–gene
interactions, or more complex combinations and variable interac-
tions. Any one of these disease-associated factors is neither suffi-
cient nor necessary to cause pancreatitis alone, but can contribute
to the disease or its complications when present within the right
context. Patients with complex diseases rarely come from large
families. Rather, the disease appears to be sporadic or occurring
in only one or two other family members. Demonstrating the eti-
ologic basis of complex genetic disorders is much more difficult
than Mendelian disorders.
The initial excitement of the discovery of three major pancre-
atitis susceptibility genes between 1996 and 2000 was followed
by slow progress in understanding pancreatic genetics, which
reflects the depth of the problem and the large number of patients
necessary to understand these complex interactions. Two major
genome-wide association studies (GWAS) have been completed
(one in Germany, and another in the United States) and the
results will soon be reported. What is clear is that the results will
either apply only to a small subset of patients, or will be important
as cofactors or modifiers in more complex interactions. However,
what is needed is a new framework from which to interpret this
data. The focus of this article is to describe the old framework and
its’ limitations, provide rationale for a new framework, and give
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examples of how this new framework can now be applied to
clinical care.
THE OLD FRAMEWORK FOR INTERPRETING
INFLAMMATORY DISORDERS
In science and medicine, a framework, or paradigm, is a theoret-
ical or conceptual structure for defining and organizing informa-
tion and relationships within a system. Rules and models within
a framework are used to understand the relationship and interac-
tion between the components, and these lead to predictions about
processes and outcomes within the larger framework.
The paradigm for western medicine in the twentieth century is
the germ theory of disease. The premise is that a single pathologic
factor causes complex disorders. The germ theory was devel-
oped following technical advances of the compound microscope
(allowing bacteria to be observed), culture and sterilization tech-
niques (e.g., work of Lister and Pasture), epidemiologic evidence
of infections causing disease (e.g., John Snow and the cholera epi-
demic in London coming from the Broad street pump), and the
work of Koch to define the process of proving that an agent causes
a disease (Koch’s postulates).
Twentieth century Western medicine was built on the germ
theory framework. Definitions of various diseases relied on tissue
pathology which was expected to reveal the underlying infectious
or parasitic agent causing inflammation or cancer. If there was
inflammation without infection, then the disorder was defined by
the type and duration of inflammation, with the expectation that
research, using Koch’s postulates, would eventually reveal the eti-
ologic factor. From a clinical setting, combinations of signs and
symptoms were used as surrogate markers of underlying pathol-
ogy, and the idea of “functional” syndromes described clinical
complaints when there was obvious tissue pathology. Thus, most
medical disorders are classified by pathology rather than etiol-
ogy, and this framework is the basis of modern disease taxonomy
(e.g., ICD-9, ICD-10 codes).
Twentieth century biomedical research was also built on the
germ theory framework. The scientific method taught in medi-
cal schools following the Flexner Report of 1910 (Flexner, 1910)
was developed for identifying a single factor that caused a com-
plex disease. The conceptual framework led to the process of
rapidly evaluating a series of potential independent factors that
were either included or excluded as the cause of disease based on
simple statistical tests (null-hypothesis significance testing). The
problem of experimental variance was addressed by increasing
study size so that the effect of the primary etiologic factor within a
population of subjects could be clearly identified. The result was a
rapid progress in understanding, defining, and organizing infec-
tious diseases, toxic agents, and Mendelian genetic traits. In each
of these cases, a single factor was responsible for a complex disease
syndrome.
The optimism of twentieth century Western medicine and
the “scientific method” following the Flexner report diminished
in the latter decades of the twentieth century when the sim-
plistic approach failed to identify single etiologic factors for
chronic inflammatory diseases, functional disorders, and cancers.
Four examples of these failures have been highlighted elsewhere
(Whitcomb, 2012), and are summarized here.
TISSUE IS THE ISSUE
A major thrust of twentieth century Western medicine was the
development and improvement of minimally invasive techniques
to obtain tissue samples in living patients since this was the basis
of disease diagnosis and treatment. Indeed, methods to obtain
biopsies by endoscopic techniques, fine needle aspirates guided
by CT, ultrasound and other techniques, laparoscopy and high-
resolution imaging techniques were perfected. However, sophis-
ticated methods of getting a tissue biopsy that were interpreted
with early twentieth century criteria did not lead to significant
improvement in medical management.
FAILED REPRODUCIBILITY
A second problem was identified when larger and more sophis-
ticated clinical studies were conducted to define the etiology
of more complex chronic diseases. The results of small and
medium sized studies were often noted to be conflicting or
non-reproducible. It was suspected that the epidemiological tech-
niques that were used in many of the studies were flawed,
and experimental design questions were raised. Evidence-based
medicine (EBM) was added to the scientific approach to address
these issues (Timmermans and Mauck, 2005). Among the many
problems of EBM is the fact that it relies on data that was col-
lected in previous trials that were designed based on theories that
were often 15–20 years out of date. Furthermore, the strict crite-
ria that are necessary for developing EBM guidelines were found
to exclude large numbers of patients and those disorders that
fell outside of the mean of the population without insight. And,
depending on the available data and criteria, different groups
who use EBM to develop guidelines often come to different con-
clusions. In reality, EBM is really more of a medical literacy
exercise than a way to provide new insights into complex diseases
(Wyer and Silva, 2009). EBM that remains within the germ-theory
paradigm will primarily be of value in simple diseases, where it
rarely provides any new insights.
MINIMAL EFFECTS OF COMMON SNPs
There has been great hope that mapping, and then sequencing
the human genome would identify the gene that causes “your-
favorite-disease”. A common approach was the GWAS, which
was developed to quickly identify the genetic variants causing a
variety of disorders and diseases (Witte, 2010). The approach,
however, was developed within the framework of the germ theory
of disease, and the scientific method of null-hypothesis signifi-
cance testing (i.e., the frequency of each genetic variant is com-
pared between cases and controls using a simple chi square or
exact test, with “significance” based on a study power calcula-
tion, adjusted for the number of other SNPs tested). However,
it was discovered that complex diseases have many genetic vari-
ants that are statistically associated with disease, but they only
have a very small effects, and the presence of absence of a SNP
in a patient usually has no clinical relevance. Furthermore, to
determine these small effect genetic variants required huge num-
bers of patients, with the expectation of a minimum of 1000
cases and 1000 controls (Ioannidis et al., 2001), and still suf-
fers from false discovery (Benjamini and Hochberg, 1995). In
more complex common diseases, tens of thousands of patients
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are being included in each arm of the study (Nettleton et al.,
2010). However, the additional data is not bringing further insight
into the disease in a way that provides clinically fashionable
insights.
INTERPRETING DATA WITHOUT STATISTICS
The final technological breakthrough is next generation sequenc-
ing (NGS). This technology has the potential of rapidly sequenc-
ing an individual’s entire DNA sequence for a few thousand
dollars. The problem with NGS is that hundreds to thousands of
unexpected genetic variants are discovered in each person’s DNA
sequence, and it is impossible to demonstrate the effect of each
variant based on statistical methods. Together, these technology
breakthroughs illustrate the inadequacy of the twentieth century
western medicine disease paradigm interpretation of complex
disorders in a germ theory model.
THE NEW FRAMEWORK FOR TWENTY-FIRST CENTURY
MEDICINE
The great frontier in CP is applied physiology. The new frame-
work needed for medicine is based on integrative physiology,
cell biology, systems modeling, and simulation of biological pro-
cesses in individuals where multiple variables associated with
various components of a system, or the external forces that
influence them, are considered in individual patients (i.e., indi-
vidualized or personalized medicine). The need to move away
from research based on null-hypothesis significance testing and
toward modeling is being recognized (Rodgers, 2010), but the
current approaches of systems biology at a molecular level
are likely unnecessary in disease modeling (Whitcomb, 2012).
Furthermore, the germ theory of disease does not need to be
abandoned. It needs to be placed in the context of the new
framework as a situation where the number of variants result-
ing in disease equals one. A personalized medicine approach
is needed when a syndrome is complex such that multiple
etiologies or combination of factors lead to the same pathol-
ogy, when the same pathology leads to multiple outcomes
and/or when the results of interventions are unpredictable.
Therefore, they are needed for chronic inflammatory diseases
such as CP, functional disorders such as chronic pain in
minimal change pancreatitis, and cancers including pancreatic
cancer. Personalized medicine focuses on disease mechanism
rather than association; it relies on modeling and simula-
tion rather than classification, but it will be able to pro-
vide guidance for individuals rather than for subsets of a
population.
NORTH AMERICAN PANCREATITIS STUDY 2 (NAPS2)
North American Pancreatitis Study 2 (NAPS2) is multicen-
ter study that was designed by the author in the late 1990s
in anticipation of future modeling in simulation approaches
that might prevent CP (Whitcomb et al., 2008). Rather than
using traditional classification approaches to CP the NAPS2 pro-
gram took a broad view, envisioning pre-existing risk, stochastic
events initiating an inflammatory process that was manifest clin-
ically by episodes of recurrent acute pancreatitis or recurrent
pain [i.e., the sentinel acute pancreatitis event (SAPE) hypoth-
esis model (Whitcomb, 1999; Yadav and Whitcomb, 2010)].
Continuation and variations of inflammatory progresses then
resulted in a constellation of variations in specialized cell and
systems with dysfunctions recognized as of different clinical com-
plications. Activation of pancreatic stellate cells leads to fibrosis.
Acinar cell loss or dysfunction results in diminished digestive
enzyme production with maldigestion. Islet cell dysfunction leads
to endocrine failure with diabetes. Nerve injury and pathologic
adaptation leads to chronic pain syndrome, and abnormal tran-
sition of inflamed pancreatic acinar-duct cells leads to pancreatic
cancer (Figure 1).
Prior to NAPS2, there was no systematic way to classify suscep-
tibility factors, other risk factors or combinations of factors. An
etiologic-based classification system had to be invented which is
known as the TIGAR-O system (Etemad and Whitcomb, 2001),
which classifies factors as either Toxic-metabolic (e.g., alcohol,
smoking), Idiopathic (e.g., tropical pancreatitis, early or late
onset), Genetic, Autoimmune, Recurrent-acute or severe (e.g.,
95% pancreatic necrosis in acute pancreatitis) or Obstructive.
This is contrast to the definitions of the Marseille classification
system that defines acute pancreatitis and CP by traditional clin-
ical and pathologic criteria (Sarles, 1965; Singer et al., 1985) and
the Cambridge classification system (Sarner and Cotton, 1984)
which defines ages of progressive destruction but provides no
insight into the mechanism of disease.
FIGURE 1 | SAPE progression model. (A) Normal histology. Patients
may have genetic risk factor and alcoholism but without pancreatic
inflammation. (B) Acute pancreatitis is triggered by a stochastic injury
(e.g., gallstone) leading to acute pancreatitis with activation of the
innate immunes system a recruitment of inflammatory cells. A variety of
modifying factors and variables (triangle) determine the resolution of acute
pancreatitis, or contribute to a variety of pathways that lead to the
recognized components of the chronic pancreatitis syndrome. (C) Chronic
pancreatitis reflects irreversible damage manifests by the response of
multiple cell types.
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The rate of progression from first symptom to the diagnosis
of CP or evidence of exocrine or endocrine failure and can-
cer was considered to be important. The NAPS2 questionnaires
were designed to facilitate construction of timelines, with the
dates of key events recorded so that the CP could be mod-
eled as a disease process rather than a diagnosis, and the effect
of interventions evaluated. This was put within the framework
of the SAPE hypothesis in contrast to using a diagnosis ICD9
577.1 alone. By modeling pancreatitis as an evolving process,
susceptibility factors and the types of stochastic events that ini-
tiate the process could be identified and quantified, and the role
of an acute pancreatitis event and other variables that initiate
and drive the progression to CP could be organized, measured,
and studied in a series of individual patients. Thus, multiple
variables could easily be classified as risk factors, biomarkers,
endpoints, or surrogate endpoints and used for constructing
predictive models which anticipated the development of compli-
cations and allow for etiology based treatments to prevent the
progression of diseases before the symptoms develop. In addi-
tion, biological samples from consecutive patients were collected
and processed for DNA and serum and/or plasma for biomarker
studies.
The utility of this approach has been remarkable. It has
allowed the North American Pancreatic Study Group to sub-
divide CP into etiology-based processes that all have the same
clinical appearance and pathologic features. This allows for early
recognition process and targeting the etiology rather than the
symptoms. Much of the data from the first 1000 patients has
now been published. Surprisingly, there appear to be a thresh-
old for risk of alcoholic pancreatitis at five more drinks per
day (60 ounces of alcohol per day), and only 15% of total
patients of all patients drank at this level (Yadav et al., 2009;
Cote et al., 2010). The majority of these patients were in the
CP group and very few were in the recurrent acute pancreati-
tis group, suggesting that alcohol also caused rapid progression
from recurrent acute to CP so that in a cross sectional study,
the pancreatitis category was markedly enriched. Smoking was
also found to be a strong, independent, and synergistic risk fac-
tor for CP which is often not recognized by general practitioners
as well as experts in CP (Yadav et al., 2011). Genetic etiologies
(CFTR, SPINK1, and PRSS1) contributed to about 25% of the
total cases (Whitcomb, 2011). More interesting was that about
40% of patients were idiopathic. These are the ones for whom
we believe complex and environmental factors play a more dom-
inate role. We expect that GWAS will bring further insight into
this category.
MODELING CHRONIC PANCREATITIS
The framework for beginning to build models of pancreatic dis-
ease includes classifying patients as combinations of factors that
occur together, in distinction to factors that are only seen together
by chance (Aoun et al., 2008). Figure 2 is a working model
of etiology-based pathway in which two factors are required
to drive the macrophages and pancreatic stellate cells to cause
fibrosis.
As seen in the figure, alcohol plus a second factor markedly
increases the risk of fibrosis. Trypsin-related pathways can begin
either in the acinar cell or in the duct and these appear to con-
verge with high risk being linked to secondary factors such as
SPINK1. Lipase and lipid metabolism disorders may represent a
separate pathway with liptoxicity or other factors directly caus-
ing pancreatic injury and CP as well as other mechanisms that are
FIGURE 2 | Complex pathways to fibrosis. A combination of two or
more factors that together markedly increase the likelihood that fibrosis
will develop. For fibrosis to occur the risk factor combination must
converge on the inflammatory cells (e.g., macrophages, Mφ; pancreatic
stellate cells, PSC). Note that alcohol can increase susceptibility to
pancreatitis by acting on the acinar cell and/or duct cell, but appears to
drive CP through another SPINK1-independent pathway (Aoun et al.,
2008).
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yet to be fully defined. These organization diagrams can set the
stage for assigning relative effect strengths to various components
of primary and secondary factors as well as other environmental
and metabolic effects that may alter the rate of progression from
the onset of pancreatitis to fibrosis. The most important of these
to-be-named variables are genetic variants.
NGS is an enabling technology for rapidly revealing all vari-
ants in the genome of an individual patient. The complexity of
the human genome has been recognized, and it is further recog-
nized that it will be nearly impossible to evaluate variants of entire
genome of an individual statistically. The challenges in analysis of
NGS for most disorders, especially those with confounding envi-
ronmental variables, are almost insurmountable. However, this is
not true for the pancreas.
The advantage of developing methods for NGS analysis in the
pancreas is that it is a very simple organ in which the exocrine
pancreas has two primary cell types, the duct cell and the acinar
cell. Each of the two cell types has a primary function (bicar-
bonate secretion or enzyme synthesis). The mechanism of injury
is trypsin activation in most cases. The time of initial injury is
often known, and the immune response is fairly stereotypic. Thus,
for trypsin related susceptibility factors, five major genes have
been identified that have been associated with patients with CP.
In addition to PRSS1, CFTR, and SPINK1, the CTRC and CASR
genes are additional risk factors that appear to increase risk of
pancreatitis in the context of one of three primary susceptibil-
ity factors (Larusch and Whitcomb, 2011; Schneider et al., 2011;
Rosendahl et al., 2012). As noted in Figure 2, the CTRC is envi-
sioned to be linked to the trypsin pathway where as the CASR
gain of function mutations are found in alcoholic patients, and
CASR loss of function mutations are found in trypsin-associated
pathways. The advantage of using NGS is that it is less expen-
sive to use whole exome sequencing for the entire 30,000+ genes
than it is to sequent CFTR using standard sanger sequencing
technology. We already demonstrated the utility in a family with
idiopathic HP (Larusch et al., 2012). This case demonstrated that
four risk factors combined in different patients within the family
tree in complex ways to cause pancreatitis from slightly differ-
ent etiologies in each of the four affected individuals. This was
done by focusing on the five known susceptibility genes rather
than analyzing the entire human genome. What was amazing is
that unexpected variants were found in these patients including
a copy number variant of the PRSS1 gene in one patient, a rare
SPINK1 mutation that had only been described in two French
patients in early 2004 (Le Marechal et al., 2004), a strong effect
of smoking, and a CFTR variant that is considered mild vari-
able may be associated with pancreatitis disease (Larusch et al.,
2012). This is a powerful proof of principle to illustrate a prac-
tical approach to the use of NGS for pancreatic disease. Of note,
cautionmust be takenwhen evaluating PRSS1 variants using NGS
since disease-causing mutations are often gene conversion muta-
tions from different forms of trypsin or trypsin pseudo-genes
(Chen and Ferec, 2000) so that there is a high risk of variants in
the trypsin genes being identified in these patients. Therefore, we
always use very specific methods to confirm true mutations in the
PRSS1 genes when analyzing patients at risk for pancreatitis.
The final question is whether or not this new framework is
compatible with clinical practice. At the University of Pittsburgh
we have reorganized our pancreas clinic so that genetic test-
ing occurs very early in the workup rather than at the end
(Whitcomb, 2012). In our experience and in the NAPS2 study
(unpublished, Whitcomb et al., 2012) we have found that there
is often a delay of 6–10 years between the onset of symptoms and
the development of CP to the point where a diagnosis could be
made. The diagnosis of CP requires irreversible damage to the
pancreas, which is exactly what we are trying to avoid! The 6 year
delay does not mean that there is no disease; it means that the cri-
teria of the old paradigm have not been met. Use of genetic testing
identifies what part of normal physiology is likely to be disrupted
by genetic variation and has implications for which cell type is
likely to be the culprit in initiating the pathology. Therefore,
attention to either the large ducts, the small pancreatic ducts,
the acinar cell, or the immune system before the destruction of
the pancreas allows targeted therapies to be initiated that address
the etiology rather than covering the symptoms. We believe that
this is a new paradigm for approaching complex inflamma-
tory disease with late complications that should be avoided at
all costs.
How can physicians receive and interpret the flood of informa-
tion that is expected to come with whole genome sequencing and
new “omics” biomarkers? The answer is that this is clearly impos-
sible. What is needed is the development of decision support tools
that are able to rapidly scan all of the information from an indi-
vidual patients genome and biomarker studies, structure it in an
organized way, perform calculations and simulations, and provide
the physician with a few options, their likelihood of being suc-
cessful, and how to best monitor the patient if interventions are
made. The role of the physician will also be to use their own train-
ing and clinical experience to help guide the treatment of patients
in whom there are no helpful predictions. Thus, there will be a lot
to discover and apply in twenty-first century medicine.
SUMMARY
We believe that genetics will be the foundation of clinical man-
agement of pancreatic diseases in the future. New recognition that
the development of CP is associated with a limited number of eti-
ologies, and recognition that there may be several years between
the first symptoms and organ destruction is a call to develop early
and effective interventions that are based on the etiology rather
than symptoms and complications. While the full spectrum of
genetic variants that is linked to pancreatic disease or have not
yet been described, the new framework that is necessary for their
interpretation is already here.
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